Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432 - Concepedia

Concepedia

Publication | Open Access

Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432

DOI Full Paper Access

466

Citations

14

References

2019

Year

F. Wang, Xiaoli Wei, Fenggong Wang, Nong Xu, Lin Shen, Guanghai Dai, Xianglin Yuan, Y. Chen, S. Yang, Jiawei Shi,

Annals of Oncology

References

	Year	Citations

Page 1